Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2018-09-12 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于非公开发行股票预案（二次修订稿）披露的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding a non-public stock issuance plan (private placement) by Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It references the disclosure of the plan on a regulatory website and clarifies that the announcement does not represent approval by regulatory authorities. The document length is only 458 characters, indicating it is a brief notice rather than the full plan or detailed financial report. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2018-09-12 Chinese
华普天健会计师事务所（特殊普通合伙）《关于请做好安徽安科生物工程（集团）非公开发行股票发审委会议准备工作的函》有关财务问题的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed letter from an accounting firm to the China Securities Regulatory Commission regarding the financial and technical review of a company's non-public stock issuance plan. It includes extensive financial data, project descriptions, risk assessments, and investment justifications related to the company's fundraising and capital use. The content focuses on the verification of financial and operational aspects of the company's capital raising activities, specifically a non-public stock issuance. It is not a full annual or quarterly report, nor an earnings release or call transcript. It is not a simple announcement or certification but a comprehensive audit-related review and opinion on the financial and project aspects tied to a capital raising event. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to financing activities but excludes full annual reports. The document length (15,000 characters) and detailed financial and operational analysis support this classification with high confidence. H1 2018
2018-09-12 Chinese
关于第六届董事会第十四次（临时）会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at a board meeting of Anhui Anke Biological Engineering (Group) Co., Ltd. It details decisions related to adjustments in a non-public stock issuance plan, voting results, and references to further detailed announcements on a regulatory disclosure website. The document is short (1996 characters) and primarily serves as a formal announcement of board decisions rather than containing detailed financial data or the full report itself. It does not contain comprehensive financial statements or detailed analysis but rather summarizes board resolutions and voting outcomes. Therefore, it fits best as a Regulatory Filing (RNS) since it is a formal regulatory announcement of board decisions and related disclosures, not a full report or presentation.
2018-09-12 Chinese
关于收到《关于请做好安徽安科生物工程（集团）非公开发行股票发审委会议准备工作的函》并回复的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the receipt of a letter from the China Securities Regulatory Commission (CSRC) about preparations for a non-public stock issuance review meeting. It includes the company's response to the CSRC's letter and mentions that the non-public stock issuance requires CSRC approval, with uncertainty about approval. The document is short (693 characters) and primarily concerns a regulatory communication and update on a financing activity (non-public stock issuance). It does not contain financial statements or detailed financial data but is an update on a capital raising process. Therefore, it fits best under Capital/Financing Update (CAP).
2018-09-12 Chinese
非公开发行股票募集资金使用可行性分析报告（二次修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "非公开发行股票募集资金使用可行性分析报告（二次修订稿）" which translates to "Non-public issuance of shares fundraising feasibility analysis report (second revision)". It details the use plan for funds raised through a non-public stock issuance, including investment projects, their necessity, feasibility, investment estimates, government approvals, and economic benefit evaluations. The document is focused on capital raising and the planned use of those funds, which aligns with a capital/financing update rather than a full financial report or annual report. There is no indication of full financial statements or comprehensive financial performance data. The document length is 8491 characters, which is substantive and contains detailed project and financing information. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2018-09-12 Chinese
关于非公开发行股票摊薄即期回报及填补回报措施（二次修订稿）的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding a non-public issuance of shares, specifically addressing the dilution of immediate returns and measures to compensate for this dilution. It includes detailed financial impact analysis, risk disclosures, the necessity and rationale for the issuance, investment project details, company commitments, and regulatory references to Chinese securities authorities. The content focuses on capital raising activities, share issuance, and related financial and governance implications. It is not a full annual or interim report, nor an earnings release or management discussion. It is not a proxy statement or voting result announcement. The document is a comprehensive update on a capital financing event, including the issuance plan, impact, and mitigation measures. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (8289 characters) and detailed content confirm it is not a mere announcement of a report but a substantive disclosure on financing.
2018-09-12 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.